Another GLP-1/GIP/glucagon receptor triagonist known as retatrutide (previously LY3437943) was developed by Eli Lilly in 2022 leading to weight loss, reduced fat mass, decreased blood glucose and insulin levels in obese mice, which was attributed to increased energy expenditure and lipid oxidation [62]
Immunity 39, 372385
163 Low-FODMAP Diet FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) are poorly absorbed carbohydrates that draw water into the small intestine and/or are fermented by bacteria in the large intestine, producing hydrogen gaseffects that may cause digestive symptoms
Insurance plans usually cover tirzepatide (Mounjaro) for the management of type 2 diabetes mellitus in adults, but often do not cover tirzepatide (Zepbound) for weight loss and require prior authorization before approval
Monitoring: Metabolic: Monitor for signs/symptoms of hypoglycemia GI: Monitor for signs/symptoms of pancreatitis after starting therapy Renal: Monitor renal function in patients with renal dysfunction reporting severe adverse GI reactions (especially when starting or escalating doses) Patient advice: Read the US FDA-approved patient labeling (Medication Guide and Instructions for Use)
If your employers plan has a specific exclusion, Aetna is contractually obligated to deny coverage
